John Concato, MD, FACP, MS, MPH
Professor AdjunctCards
Appointments
Additional Titles
Associate Director, Office of Medical Policy, Center for Drug Evaluation & Research, Food and Drug Administration
Contact Info
Appointments
Additional Titles
Associate Director, Office of Medical Policy, Center for Drug Evaluation & Research, Food and Drug Administration
Contact Info
Appointments
Additional Titles
Associate Director, Office of Medical Policy, Center for Drug Evaluation & Research, Food and Drug Administration
Contact Info
About
Titles
Professor Adjunct
Positions outside Yale
Associate Director, Office of Medical Policy, Center for Drug Evaluation & Research, Food and Drug Administration
Biography
Dr. Concato is Associate Director for Real-World Evidence Analytics in the Office of Medical Policy (OMP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA). After conducting clinical research studies for more than 25 years as an independent investigator and research center director at Yale University & the Department of Veterans Affairs, he now develops, coordinates, and implements medical policy programs and strategic initiatives, with a focus on real-world evidence (RWE). These efforts include overseeing RWE guidance development and demonstration projects, as well as engaging external stakeholders and contributing to the review of RWE submissions, in support of the agency’s evaluation of RWE as mandated by the 21st Century Cures Act.
Appointments
General Internal Medicine
Professor AdjunctPrimary
Other Departments & Organizations
- General Internal Medicine
- Internal Medicine
- Yale Ventures
Education & Training
- MPH
- Yale University, Public Health (1991)
- Fellow
- Yale University School of Medicine (1991)
- Resident
- New York University School of Medicine (1989)
- MD
- New York University (1985)
- MS
- New York University, Environmental Health (1981)
Research
Overview
Medical Research Interests
ORCID
0000-0003-2846-0503
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Mihaela Aslan, PhD
Theodore Holford, PhD
Mary Tinetti, MD
Nallakkandi Rajeevan, PhD
Patrick G. O'Connor, MD, MPH, MACP
Sidney Tuttle Bogardus, MD
Research Design
Prognosis
Publications
2024
Prescription Medication Use Among Older Adults in the US
Innes G, Ogden C, Crentsil V, Concato J, Fakhouri T. Prescription Medication Use Among Older Adults in the US. JAMA Internal Medicine 2024, 184: 1121-1123. PMID: 38949837, PMCID: PMC11217884, DOI: 10.1001/jamainternmed.2024.2781.Peer-Reviewed Original ResearchCitationsAltmetricUse of Sensitivity Analyses to Assess Uncontrolled Confounding from Unmeasured Variables in Observational, Active Comparator Pharmacoepidemiologic Studies: A Systematic Review
Latour C, Delgado M, Su I, Wiener C, Acheampong C, Poole C, Edwards J, Quinto K, Stürmer T, Lund J, Li J, Lopez N, Concato J, Funk M. Use of Sensitivity Analyses to Assess Uncontrolled Confounding from Unmeasured Variables in Observational, Active Comparator Pharmacoepidemiologic Studies: A Systematic Review. American Journal Of Epidemiology 2024, kwae234. PMID: 39098826, DOI: 10.1093/aje/kwae234.Peer-Reviewed Original ResearchAltmetricConceptsUncontrolled confoundingEpidemiology journalsResidual confoundingSystematic reviewRobustness of studiesComparative cohort studyActive comparator cohort studyMedical journal articlesCohort studyConfoundingJournal articlesPharmacoepidemiological studiesSensitivity analysisPotential biasAssess robustnessMeasured variablesUnmeasured variablesPotential concernReview articleStudyJournalsVariablesQualitative Analysis of Inquiries Received by FDA Regarding Conduct of Clinical Trials during the Covid-19 Public Health Emergency
Kambere M, Vu H, Kappel D, Oh K, Budashewitz P, Concato J. Qualitative Analysis of Inquiries Received by FDA Regarding Conduct of Clinical Trials during the Covid-19 Public Health Emergency. Therapeutic Innovation & Regulatory Science 2024, 58: 987-995. PMID: 38913114, PMCID: PMC11335776, DOI: 10.1007/s43441-024-00674-x.Peer-Reviewed Original ResearchConceptsCOVID-19 public health emergencyPublic health emergencyFood and Drug AdministrationTrial participantsHealth emergencyClinical practice guidelinesAnalysis of inquirySafety of trial participantsClinical trialsTrial-related activityPractice guidelinesCOVID-19Industry trade associationsConduction of clinical trialsU.S. Food and Drug AdministrationClinical practiceInterested partiesTrade associationsPartiesMedical productsBackgroundThis reportRelated guidanceParticipantsQualitative methodsDrug AdministrationCorrelates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder
Bigdeli T, Barr P, Rajeevan N, Graham D, Li Y, Meyers J, Gorman B, Peterson R, Sayward F, Radhakrishnan K, Natarajan S, Nielsen D, Wilkinson A, Malhotra A, Zhao H, Brophy M, Shi Y, O’Leary T, Gleason T, Przygodzki R, Pyarajan S, Muralidhar S, Gaziano J, Huang G, Concato J, Siever L, DeLisi L, Kimbrel N, Beckham J, Swann A, Kosten T, Fanous A, Aslan M, Harvey P. Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder. Molecular Psychiatry 2024, 29: 2399-2407. PMID: 38491344, DOI: 10.1038/s41380-024-02472-1.Peer-Reviewed Original ResearchCitationsAltmetricConceptsBipolar I disorderSuicidal behaviorElectronic health recordsPolygenic scoresVeterans Health AdministrationSelf-reported SBColumbia-Suicide Severity Rating ScaleBipolar I disorder patientsCorrelates of suicidal behaviorClasses of psychotropic medicationsSelf-injurious behaviorHealth recordsSeverity Rating ScaleDiagnosed mental illnessAssociated with clinical variablesElectronic health record codesEHR domainDepressive disorderC-SSRSLifetime diagnosisSubstance-relatedPsychotropic medicationsSuicidal ideationExternalizing behaviorsSuicide attemptsClinical Interviewing: An Essential but Neglected Method of Medicine
Fava G, Sonino N, Aron D, Balon R, Montiel C, Cao J, Concato J, Eory A, Horwitz R, Rafanelli C, Schnyder U, Wang H, Wise T, Wright J, Zipfel S, Patierno C. Clinical Interviewing: An Essential but Neglected Method of Medicine. Psychotherapy And Psychosomatics 2024, 93: 94-99. PMID: 38382481, DOI: 10.1159/000536490.Peer-Reviewed Original ResearchCitationsConceptsClinical interviewIncrease patient motivationHealthy behaviorsMethods of medicineSelf-managementClinical encountersPatient motivationClinical processesPatient informationQuality of interviewsEducational trainingLack cost effectivenessClinical domainsPresenting complaintMedical historyInterviewsPhysiciansLife settingsTime pressureQuality of dataPersonal attitudesPatientsCost-effectiveExpensive testsDecision makingThe Million Veteran Program 1990–1991 Gulf War Era Survey: An Evaluation of Veteran Response, Characteristics, and Representativeness of the Gulf War Era Veteran Population
Harrington K, Quaden R, Steele L, Helmer D, Hauser E, Ahmed S, Aslan M, Radhakrishnan K, Honerlaw J, Nguyen X, Muralidhar S, Concato J, Cho K, Gaziano J, Whitbourne S, Program O. The Million Veteran Program 1990–1991 Gulf War Era Survey: An Evaluation of Veteran Response, Characteristics, and Representativeness of the Gulf War Era Veteran Population. International Journal Of Environmental Research And Public Health 2024, 21: 72. PMID: 38248536, PMCID: PMC10815483, DOI: 10.3390/ijerph21010072.Peer-Reviewed Original ResearchCitationsConceptsGulf War IllnessMillion Veteran ProgramVeteran populationVeterans Health Administration (VHA) servicesHealth conditionsComparable health statusLarge research cohortsVA Million Veteran ProgramSimilar medical conditionsHigher socioeconomic statusGW veteransMean ageVHA servicesHealth characteristicsMedical conditionsEligible veteransHealth statusResearch cohortCohortSocioeconomic statusVeterans' responsesVeteransVeteran ProgramBroader populationFull population
2023
Comparison of two assessments of real‐world data and real‐world evidence for regulatory decision‐making
Yuan L, Rahman M, Concato J. Comparison of two assessments of real‐world data and real‐world evidence for regulatory decision‐making. Clinical And Translational Science 2023, 17: e13702. PMID: 38093484, PMCID: PMC10766019, DOI: 10.1111/cts.13702.Peer-Reviewed Original ResearchCitationsAltmetricConceptsReal-world evidenceEuropean Medicines AgencyDrug approvalOpen-label extension studyNon-interventional studySingle-arm trialClinical trial implementationUnited States FoodInterventional trialsComparator armDrug AdministrationMedicines AgencyExtension studyStudy designUse of RWEStates FoodPharmacovigilance activitiesTrialsRegulatory agenciesApprovalLack of agreementTrial implementationLiterature reviewTherapeutic contextReal-world dataMetformin prescription for U.S. veterans with prediabetes, 2010–2019
Gulanski B, Goulet J, Radhakrishnan K, Ko J, Li Y, Rajeevan N, Lee K, Heberer K, Lynch J, Streja E, Mutalik P, Cheung K, Concato J, Shih M, Lee J, Aslan M. Metformin prescription for U.S. veterans with prediabetes, 2010–2019. Journal Of Investigative Medicine 2023, 72: 139-150. PMID: 37668313, DOI: 10.1177/10815589231201141.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsBody mass indexVeterans Health AdministrationIncident prediabetesHigh riskHealth AdministrationRetrospective observational cohort studyType 2 diabetes mellitusUse of metforminObservational cohort studyProportion of veteransMetformin prescribingGestational diabetesCohort studyMetformin prescriptionDiabetes mellitusDiabetes preventionMass indexCardiovascular diseaseMultivariable modelPrediabetesSubset of individualsMetforminU.S. veteransHealthcare systemVeteransDecisions on Non-oncology Breakthrough Therapy Designation Requests in 2017–2019
Poddar A, Raggio M, Concato J. Decisions on Non-oncology Breakthrough Therapy Designation Requests in 2017–2019. Therapeutic Innovation & Regulatory Science 2023, 58: 214-221. PMID: 37926768, PMCID: PMC10764372, DOI: 10.1007/s43441-023-00589-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBreakthrough therapy statusTherapy statusInsufficient treatment effectNon-oncology drugsReview of requestsUnmet medical needInadequate study designBreakthrough therapy designationConclusionsThis analysisCommon reasonInvestigational drugsUS FoodMedical needOrphan diseaseStudy designDrug evaluationMarketing approvalCorresponding drugsDrugsApproval statusTreatment effectsDrug developmentFDA processDesignation programStatusReal-World Evidence for Neonatal Drug Development: Challenges and Opportunities
Singh K, Concato J, Davis J. Real-World Evidence for Neonatal Drug Development: Challenges and Opportunities. The Journal Of Pediatrics 2023, 265: 113806. PMID: 37918517, DOI: 10.1016/j.jpeds.2023.113806.Peer-Reviewed Original ResearchCitationsAltmetric
News
News
- August 08, 2016
Million Veterans Program now world's largest genomic biobank
- May 08, 2015
Building a biobank … a million veterans at a time
- September 15, 2009
Markers for prostate cancer
- May 04, 2009
Molecular Markers May Help Physicians Predict Severity of Prostate Cancer